AS our population ages, concerns about frailty and
|
|
- Marilynn Howard
- 5 years ago
- Views:
Transcription
1 Journal of Gerontology: MEDICAL SCIENCES 2004, Vol. 59A, No. 5, Copyright 2004 by The Gerontological Society of America Special Article Masculine Vitality: Pros and Cons of Testosterone in Treating the Andropause Sanjay Asthana, 1 Shalendar Bhasin, 2 Robert N. Butler, 3 Howard Fillit, 4 Joel Finkelstein, 5 S. Mitchell Harman, 6 Lana Holstein, 7 Stanley G. Korenman, 8 Alvin M. Matsumoto, 9 John E. Morley, 10 Panayiotis Tsitouras, 6 and Randall Urban 11 1 University of Wisconsin Medical School, Madison. 2 Charles R. Drew University of Medicine and Science, Los Angeles, California. 3 International Longevity Center-USA, Alliance for Health & the Future, New York. 4 Institute for the Study of Aging, New York. 5 Harvard Medical School, Cambridge, Massacusetts. 6 Kronos Longevity Research Institute, Phoenix, Arizona. 7 Miraval Life in Balance Resort, Tucson, Arizona. 8 UCLA School of Medicine, Los Angeles, California. 9 VA Puget Sound Health Care System, Seattle, Washington. 10 Saint Louis University School of Medicine, St. Louis, Missouri. 11 University of Texas Medical Branch in Galveston. AS our population ages, concerns about frailty and disability, as well as the all-too-human desire to remain young for as long as possible, have led increasing numbers of women and men to the questionable practice of restoring diminishing hormone levels. Recent research findings have highlighted the health risks of oral estrogen progestin combination therapy in older women. To date, however, no serious long-term randomized trials of sufficient size to examine the effects of testosterone replacement on men have been conducted, nor is it clear what role the observed decline in total and bioavailable testosterone plays in male aging. Currently, the long-term clinical beneficial effects of testosterone replacement in older men are poorly defined, and the magnitude of risks for prostate and heart disease remain largely unknown. Because of these uncertainties, the academic community is in agreement that large-scale definitive studies are needed. In contrast, the media and the public at large appear to have moved beyond science in this field. A recent market analysis indicates that testosterone sales were expected to reach $400 million in 2002 (1). Upward trends in the sales of testosterone products are likely to persist and even grow in the foreseeable future. Thus, it is extremely important for the scientific community to develop a consensus about the health benefits and safety of these products. The purposes of this special article are to: 1) summarize what we already know about the andropause and the effects of testosterone replacement therapy; 2) propose a research agenda for future work; and 3) identify other steps that might be taken in the realm of public information and policy. For a more detailed treatment of these issues, see the International Longevity Center Workshop Report, which is available at BIOCHEMISTRY AND METABOLISM OF TESTOSTERONE Little proof exists to support the hypothesis of andropause the so-called male menopause. Unlike women, whose estrogen levels precipitously decline beginning in their fourth decade, men exhibit a wide range of testosterone levels throughout life. Serum levels of total and free testosterone increase during puberty, reaching a maximum in the twenties and thirties, then generally decline steadily at approximately 1% per year with increasing age. A critical factor in evaluating the biologic effectiveness of testosterone is the circulating concentration of bioavailable testosterone. This factor, the fraction of circulating testosterone that is not tightly bound to sex hormone-binding globulin, is considered to be the biologically active component that actually enters cells, interacts with intracellular androgen receptors, and, in that manner, regulates gene expression and cellular function. Testosterone is actively metabolized to estradiol, a potent estrogen, and to dihydrotestosterone, an androgen more potent than testosterone. The role of each in mediating the effects of circulating testosterone on target tissues and biological function, especially as a function of aging, is not well understood (2). AGE-RELATED CHANGES IN TESTOSTERONE FUNCTION By the seventh to eighth decade of life, a significant number of otherwise healthy men have levels of free or bioavailable testosterone that, if observed in men under the age of 45, would undoubtedly lead to their classification as hypogonadal. The extent to which this observed reduction in testosterone levels contributes to loss of bone, lean body/skeletal muscle mass, gain in body fat, and frailty remains to be determined. Preliminary evidence suggests 461
2 462 ASTHANA ET AL. that testosterone replacement has some potential to reduce these concomitants of aging in men, but the interactions of testosterone with diet, exercise, and other hormone deficiencies or excesses characteristic of aging are largely unexplored. DEFINITION OF HYPOGONADISM Men with total and/or bioavailable testosterone levels below the normal range (defined statistically based on measurements in large numbers of young men) are currently classified as hypogonadal. The Endocrine Society s Second Annual Andropause 2001 meeting reports: Total testosterone levels, 200 ng/dl clearly indicate hypogonadism, and in most instances indicate that benefits may be derived from testosterone replacement therapy...if a healthy man has a serum testosterone level. 400 ng/dl, it is unlikely he is testosterone deficient. [Note that recent data suggesting an upper value of 500 ng/dl may be more appropriate (3).] As a corollary, values between 200 and 500 ng/dl may be considered questionable for hypogonadism and suggest a need for further evaluation in men with symptoms of testosterone deficiency. Members of the Endocrine Society can access the full report at www. endosociety.org/membersonly.cfm To properly define hypogonadism, however, functional as well as biochemical criteria should be used rather than this type of statistical construct. Appropriate criteria would include low serum levels of bioavailable testosterone as well as subjective physiological changes consistent with androgen deficiency, such as reduced muscle mass or strength, reduced bone mass, and reduced libido. It is quite possible that the relationship between circulating testosterone levels and various physiological endpoints differs for each system. Thus, a level of testosterone that is sufficient to support libido may be inadequate to maintain bone mineral density or muscle mass. Unfortunately, at the time of this report, insufficient data exist to rigorously identify levels of total bioavailable testosterone that define physiological or functional hypogonadism for most target organs and tissues or for men of different ages. Research to address this problem and the related problem of accuracy and reliability of assays for total and bioavailable testosterone should be a high priority. TESTOSTERONE REGULATION OF SKELETAL MUSCLE A common finding of studies of hypogonadal young men, as well as older men with age-related declines in testosterone, is reduced lean body mass. The observation that testosterone supplementation in both young and older men increases muscle mass suggests that testosterone may play an important role in the preservation of muscle mass (4 8). Testosterone effects on the muscle are highly correlated with the administered dose of testosterone and the resulting testosterone concentrations (9). Previous studies in older men used relatively small doses of testosterone (6,8,10); these studies demonstrated modest gains in fat-free mass, a significant decrease in fat mass, but inconsistent changes in muscle strength. Testosterone supplementation is associated with hypertrophy of both type I and type II muscle fibers, and a dose-dependent increase in the number of myonuclei and satellite cells (11). Androgens increase muscle mass by promoting the commitment of mesenchymal pluripotent cells into the myogenic lineage and inhibiting the differentiation of these cells into the adipogenic lineage (12). In addition, testosterone stimulates muscle protein synthesis and improves the reutilization of amino acids by the skeletal muscle (13). The molecular mechanisms that mediate the anabolic effects of androgens are poorly understood. Further studies are needed to determine whether testosterone supplementation improves physical function and health-related outcomes in individuals at risk for disability. EFFECT OF TESTOSTERONE ON BONE DENSITY As men age, their bone mineral density declines and they become vulnerable to fractures (14 16). It is unclear the extent to which this decline is related to the age-related changes in testosterone versus other bone-regulating factors (e.g., parathyroid hormone, vitamin D, growth hormone) (17 20). One study conducted to determine testosterone s role in increasing spinal bone density suggested that testosterone increased bone mineral density only in men whose serum testosterone levels were particularly low before treatment (21). Although research suggests that testosterone replacement may benefit some older men, further studies are needed. TESTOSTERONE, BRAIN FUNCTION, AND COGNITION Testosterone, which crosses the blood brain barrier easily, affects brain function via androgen receptors selectively distributed throughout the brain (22). Additionally, androgens are probably synthesized in the brain and play an important role in its development, growth, maturation, and differentiation (23). The results of basic science investigations corroborate those of clinical trials and epidemiological studies. Although not universally confirmed, administration of testosterone to men with low testosterone levels has been shown to enhance specific areas of cognitive function in the majority of studies. Administration of testosterone, either by weekly injection or daily scrotal patch, significantly enhanced spatial memory, working memory, and verbal fluency of healthy older men (24 28). These results must be considered preliminary. TESTOSTERONE AND PROSTATE Among the greatest fears related to testosterone replacement for older men are increased risks for benign prostatic hyperplasia and prostate cancer (29,30). Dozens of reports from testosterone replacement studies over the last 20 years have shown no increase in prostate cancer. However, definitive conclusions await a study of sufficient duration to answer that important question (31 36). TESTOSTERONE AND ERECTILE FUNCTION Male-type libido appears to require male levels of serum testosterone (37), and testosterone clearly improves libido when administered to older men (38). Erectile dysfunction, on the other hand, appears to be influenced by many factors, including depression, vascular and intrinsic penile disease, and autonomic neuropathy, in addition to hypogonadism.
3 ANDROPAUSE 463 Thus, although no direct relationship between hypogonadism and human erectile dysfunction has been established, they are both common manifestations of aging (39). TESTOSTERONE, INSULIN SENSITIVITY, AND THE CARDIOVASCULAR SYSTEM The effects of testosterone supplementation on a wide variety of physiological systems in older men have recently been reviewed and summarized by Morley (40). It is noteworthy that testosterone and dihydrotestosterone generally raise insulin-like growth factor levels and lean body mass while decreasing fat mass. They also lower serum total cholesterol and low-density lipoprotein, but also diminish high-density lipoprotein. Coronary artery disease has been associated with low testosterone levels in men (41), although cause and effect have not been established. Adequately powered long-term studies are needed to determine the deleterious and beneficial effects of testosterone treatment on the cardiovascular system. THE NEED FOR A LARGE CLINICAL STUDY Given the increasing use of testosterone by the public, it is crucial to establish the risk/benefit ratio of testosterone replacement therapy so that patients and doctors can make informed choices. No studies to date have included a sufficient number of participants to adequately make these assessments. A large-scale prospective randomized, placebo-controlled trial with approximately 6000 participants (3000 taking testosterone, with an equal number taking placebo) has been proposed by a consortium of academic andrologists to ascertain changes in the incidence of prostate cancer and coronary events. This number of participants, based on the need to define possible risks, should be enough to firmly establish the possible benefits of testosterone replacement therapy. The need to conduct a large-scale clinical trial is underscored by the history of hormone replacement therapy (estrogen plus progesterone) in women. Decades of epidemiologic research led to widespread use of this treatment for postmenopausal women. Only recently, as a result of randomized, placebo-controlled, large-scale clinical trials, have we come to conclude that the prior interpretation based on limited epidemiologic data may have been misleading. In a population of women, most of whom were well past the menopause, total morbidity attendant to treatment with hormone replacement therapy has been found to increase, not decrease, with greater likelihood of cardiovascular events and development of breast cancer (42). Based on these data, which could only be attained from a largescale clinical trial, millions of older women and their physicians are reassessing the wisdom of beginning or continuing on hormone replacement therapy. Similarly, a large-scale clinical trial of testosterone replacement therapy for older men is required to inform the public and physicians about the risks and benefits of treatment with testosterone. The study should focus on the response of older hypogonadal men to an extended period of testosterone replacement therapy (5 to 6 years), with measurable endpoints to include muscle mass and strength; physical functioning; bone mineral density and incidence of bone fractures; body composition; insulin sensitivity, glucose tolerance, and incidence of diabetes mellitus; cognitive function and incidence of dementia; sense of well-being and incidence of dysthymia; erythremia; sleep apnea; progression of atherosclerosis; and, most important, the incidence of cardiovascular events, e.g., myocardial infarction, stroke, and cardiac death. It would also evaluate effects on erectile function; the development of benign prostatic hypertrophy requiring invasive therapy; and the development of clinical prostate cancer. Major questions about how to conduct such a trial have been addressed in some detail (43). RESEARCH AGENDA Beyond the need for a large clinical study, additional questions need to be addressed. Assays for Testosterone Better technology is needed for assaying circulating levels of testosterone, particularly for clinical laboratories. In the absence of reliable, well-standardized methodologies for determining blood levels of testosterone and bioavailable testosterone, little progress can be made in defining agerelated hypogonadism chemically and functionally. If we cannot accurately determine which men have low biological action of testosterone based on serum measurements, then we cannot select appropriate populations to study for risk/ benefit ratios of testosterone replacement in older men. Baseline testosterone will undoubtedly be a major determinant of individuals who are likely to benefit. Screening Tests for Hypogonadism Accurate diagnostic testing must be developed. Although at least three screening questionnaires are currently in use to determine whether men are functionally hypogonadal (44 46), independent epidemiological validation of these questionnaires is lacking. A screening questionnaire based more on quantifiable symptoms of hypogonadism is needed. Clinical Trials Many earlier clinical trials have suffered from methodological shortcomings, including insufficient numbers of participants; short duration of follow-up; lack of adequate control for effects of age, race, ethnicity, medication use, and illness; and lack of standardized methods of reporting. Care must be taken to address all of these issues in any new clinical trials undertaken. The source of the androgen also requires careful consideration. Use of a testosterone gel rather than an injection has been recommended both to avoid large swings in testosterone levels leading to nonphysiological levels, and because a gel is the form most likely to be used by the public if a trial indicates safety and efficacy. Biological Studies Additional research is needed to: Identify levels of testosterone that better define physiological or functional hypogonadism for target tissues and organs Better understand the relative roles of testosterone, di-
4 464 ASTHANA ET AL. hydrotestosterone, and E2 in mediating the effects of bioavailable testosterone on these target tissues and organs Determine the number and location of androgen receptors in target tissues and organs, and learn whether these change with age Improve our knowledge of age-related changes in tissuespecific sensitivity and dose response to testosterone at both the molecular and clinical level Research is needed to better understand the molecular mechanisms for the effects of testosterone in many areas: bone mineral density, regional fat distribution and metabolism, muscle mass and strength, physical performance and function, cognitive function and mood, libido and sexual activity, cardiovascular performance, and immune function, if any. Studies in the frail elderly population are particularly needed. PUBLIC POLICY ISSUES In 2002, the Department of Veterans Affairs and the National Institute on Aging announced they would not go ahead with a planned 6000-man clinical trial to study testosterone replacement therapy in aging men. This was apparently due to concerns about whether a clinical trial could be designed that would protect the study s participants from potential health risks such as prostate cancer, heart attacks, and strokes. Such concerns are consistent with the recent report that estrogen plus progesterone replacement therapy may not be as safe as originally had been assumed (42). After evaluating the pros and cons of conducting a largescale clinical trial of testosterone therapy, an expert panel of the Institute of Medicine of the National Academies recommended going forward only with small-to-mediumsized trials to explore whether testosterone produces significant clinical benefits in older men (47). The committee recommended that any large-scale trial to determine longterm risks and effectiveness should be considered only if benefits are demonstrated in these initial studies. Unfortunately, as with hormone replacement therapy in women, the Institute of Medicine recommendation means that the evidence base from clinical outcomes studies on the long-term efficacy and safety of testosterone therapy in older men that is needed to guide clinicians will not be available for at least a decade. ACKNOWLEDGMENTS This report is based on an interdisciplinary workshop cosponsored by the International Longevity Center-USA (New York), Kronos Longevity Research Institute (Phoenix), Institute for the Study of Aging (New York), and Canyon Ranch Health Resort (Tucson). Address correspondence to Robert N. Butler, MD, International Longevity Center-USA, 60 East 86th St., New York, NY robertb@ilcusa.org REFERENCES 1. Anderson JK, Faulkner S, Cranor C, Briley J, Gevirtz F, Roberts S. Andropause: knowledge and perceptions among the general public and health care professionals. J Gerontol Med Sci. 2002;57A:M793 M Matsumoto AM. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol Med Sci. 2002; 57A:M76 M Morley JE, Patrick P, Perry HM III. Evaluation of assays available to measure free testosterone. Metabolism. 2002;51: Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992;75: Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996;81: Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999a;84: Bebb RA, Wade J, Frohlich J, Basson R, Lavery MJ, Hoens A, Copp DH. A randomized, double blind, placebo controlled trial of testosterone undecanoate administration in aging hypogonadal men: effects on bone density and body composition. Aging Male. 2000; 3(Suppl 1): Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol Med Sci. 2003;58A: Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endrocrinol Metab. 2001;281:E1172 E Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol Med Sci. 2001; 56A:M266 M Sinha-Hikim I, Roth SM, Lee MI, Bhasin S. Testosterone-induced muscle hypertrophy is associated with an increase in satellite cell number in healthy, young men. Am J Physiol Endocrinol Metab. 2003; 285:E197 E Singh R, Artaza JN, Taylor WE, Gonzalez-Cadavid NF, Bhasin S. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10G1/2 pluripotent cells through an androgen receptormediated pathway. Endocrinology 2003; Ferrando AA, Sheffield-Moore M, Yeckel CW, et al. Testosterone administration in older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002;282: E601 E Wishart JM, Need AG, Horowitz M, Morris HA, Nordin BEC. Effect of age on bone density and bone turnover in men. Clin Endocrinol. 1995; 42: Riggs BL, Wahner HW, Dunn WL, Mazess RB, Offord KP, Melton LJ III. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest. 1981;67: Zmuda JM, Cauley JA, Glynn NW, Finkelstein JS. Posterior-anterior and lateral dual-energy x-ray absorptiometry for the assessment of vertebral osteoporosis and bone loss among older men. J Bone Miner Res. 2000;15: Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002;87: Ferrini RL, Barrett-Connor E. Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am J Epidemiol. 1998;147: Denti L, Pasolini G, Sanfelici L, et al. Aging-related decline of gonadal function in healthy men: correlation with body composition and lipoproteins. J Am Geriatr Soc. 2000;48: van den Beld AW, de Jong FH, Grobbee DE, Pols HA, Lamberts SW. Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men. J Clin Endocrinol Metab. 2000;85: Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999b;84: Simerly RB, Chang C, Muramatsu M, Swanson LW. Distribution of androgen and estrogen receptor mrna-containing cells in rat brain: an in situ hybridization study. J Comp Neurol. 1990;294: Stoffel-Wagner B. Neurosteroid metabolism in the human brain. Eur J Endocrinol. 2001;145:
5 ANDROPAUSE Cherrier MM, Asthana S, Plymate S, et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 2001;57: Janowsky JS, Oviatt SK, Orwoll ES. Testosterone influences spatial cognition in older men. Behav Neurosci. 1994;108: Janowsky J, Chavez B, Zamboni B. The cognitive neuropsychology of sex hormones in men and women. Dev Neuropsychol. 1998;14: Janowsky JS, Chavez B, Orwoll E. Sex steroids modify working memory. J Cogn Neurosci. 2000;12: O Connor DB, Archer J, Hair WM, Wu FCW. Activational effects of testosterone on cognitive function in men. Neuropsychologia. 2001;39: Jeyaraj DA, Udayakumar TS, Rajalakshmi M, Pal PC, Sharma RS. Effects of long-term administration of androgens and estrogen on rhesus monkey prostate: possible induction of benign prostate hyperplasia. J Androl. 2000;21: Guay AT, Perez JB, Fitaihi WA, Vereb M. Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer. Endocr Pract. 2000;6: Levi F, La Vecchia C, Randimbison L, Erler G, Te VC, Franceschi S. Incidence, mortality and survival from prostate cancer in Vaud and Neuchatel, Switzerland, Ann Oncol. 1998;9: La Rosa F, Stracci F, Petrinelli AM, Casucci P, Mastrandrea V. Incidence, mortality and long-term survival from prostate cancer in Umbria, Italy, Eur Urol. 2000;38: Majeed A, Babb P, Jones J, Quinn M. Trends in prostate cancer incidence, mortality and survival in England and Wales, BJU Int. 2000;85: Brewster DH, Fraser LA, Harris V, Black RJ. Rising incidence of prostate cancer in Scotland: increased risk or increased detection? BJU Int. 2000;85: Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330: Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, populationbased study in Sweden. JAMA. 1997;277: Bagatell C, Heiman J, Rivier J, Bremner WJ. Effects of endogenous testosterone and estradiol on sexual behavior in normal young men. J Clin Endocrinol Metab. 1994;78: Morales A, Johnston B, Heaton JP, Lundie M. Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J Urology. 1997;157: Korenman SG, Morley JE, Mooradian AD, et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab. 1990;71: Morley JE, Perry HM. Andropause: an old concept in new clothing. Clin Geriatr Med. 2003;19: English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer K. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J. 2000;21: Writing Group for the Women Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women s Health Initiative randomized controlled trial. JAMA. 2002;288: Bhasin S, Bagatell CJ, Bremner WJ, Plymate SR, Tenover JL, Korenman SG, Nieschlag E. Issues in testosterone replacement in older men. J Clin Endocrin Metab. 1998;53: Heineman AJ, Zimmermann J, Vermeulen A, Thiel C. A new aging male s symptoms (AMS) rating scale. Aging Male. 1999;2: Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, Perry HM III. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49: Smith KW, Feldman HA, McKinlay JB. Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin Endocrinol. 2000;53: Liverman CT, Blazer DG, eds. Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy. Testosterone and Aging: Clinical Research Directions. Institute of Medicine. Washington, DC: National Academy Press; Received and Accepted February 11, 2004
Original Research Declining testicular function in aging men
(2003) 15, Suppl 4, S3 S8 & 2003 Nature Publishing Group All rights reserved 0955-9930/03 $25.00 www.nature.com/ijir Original Research 1 * 1 Wesley Woods Health Center, Atlanta, Georgia, USA Age-related
More informationDonald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May Terry s Testosterone
Focus on CME at University of Alberta ADAM: Dealing with the Decline Donald W. Morrish, MD, PhD, FRCPC Presented at Mountain Man: Men's Health Conference, May 2005 We now know there is a decline in total
More informationTestosterone Hormone Replacement Drug Class Prior Authorization Protocol
Testosterone Hormone Replacement Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective date: April 1, 2018 This policy has been developed through
More informationDrug Class Monograph
Drug Class Monograph Class: Testosterone Hormone Replacement Drug: Androderm (testosterone transdermal system), Androgel (testosterone topical gel), Axiron (testosterone topical solution), Aveed (testosterone
More informationChapter 5. General discussion
Chapter 5. General discussion 127 Chapter 5 In 2003, two review papers concluded that endogenous androgens do not show any consistent association with cardiovascular disease (CVD) risk 1,2. Apparently,
More informationInsight into male menopause'
Insight into male menopause' Dr Mark Vanderpump MD FRCP Consultant Endocrinologist Clinics: Tuesday PM Mark Vanderpump Consultant Physician and Endocrinologist Introduction Serum total and free testosterone
More informationTestosterone Hormone Replacement Drug Class Prior Authorization Protocol
Line of business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Testosterone Hormone Replacement Drug Class Prior Authorization Protocol This policy has been developed through
More informationIssues. What is a low testosterone? Who needs testosterone therapy? Benefits/adverse effects of testosterone replacement Treatment options
Male Hypogonadism Jauch Symposium Waterloo, IA May 17, 2013 Janet A. Schlechte, M.D. Disclosure of Financial Relationships Janet A. Schlechte, M.D. has no relationships with any proprietary entity producing
More informationSecrets of Abang Sado : Effects of testosterone therapy. Azraai Nasruddin
+ Secrets of Abang Sado : Effects of testosterone therapy Azraai Nasruddin + Testosterone Testosterone : Steroid hormone - Made primarily by the testicles in males - Small amounts produced by the adrenal
More informationThe ICL Insider. Lab Testing: Testosterone. In This Issue. The Debate
The ICL Insider February 2017 Volume 2, Issue 2 Lab Testing: Testosterone In This Issue Testosterone shashtilak@iclabs.ca Next Issue: Expected Release April 2017 The Debate Aging is accompanied by various
More informationNatural Hair Transplant Medical Center, Inc Dove Street, Suite #250, Newport Beach, CA Phone
Natural Hair Transplant Medical Center, Inc. 1000 Dove Street, Suite #250, Newport Beach, CA 92660 Phone-949-622-6969 Finasteride (PROPECIA ) Acknowledgement Finasteride is an oral medication, manufactured
More informationTreatment of androgen deficiency in the aging male
Treatment of androgen deficiency in the aging male The Practice Committee of the American Society for Reproductive Medicine Birmingham, Alabama Although guidelines for androgen replacement therapy for
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2018-9 Program Prior Authorization/Medical Necessity Topical Androgens Medication Axiron*, Androderm, Androgel*, Fortesta*, Natesto*,
More informationThe Science of. NUTRICULA Longevity Journal
32 December, 2011 The Science of 33 NUTRICULA Longevity Journal As men age, there is often a decline in libido and sexual function. This decline frequently interferes in intimacy within romantic relationships,
More informationJeremiah Murphy, MD Mercy Urology Clinic. October 21, 2017
Jeremiah Murphy, MD Mercy Urology Clinic October 21, 2017 Describe an appropriate strategy for the evaluation and diagnosis of male hypogonadism Endocrine Society Clinical Practice Guideline-2010 Review
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other METHYL ANDROID METHITEST METHYL TESTRED 01404 ROUTE MISCELL. CYPIONATE ENANTHATE GUIDELINES FOR USE ANDRODERM ANDROGEL AXIRON FORTESTA NATESTO STRIANT TESTIM VOGELXO
More informationTestosterone Use and Effects
Parkland College Natural Sciences Poster Sessions Student Works 2013 Testosterone Use and Effects Brandon Mills Parkland College Recommended Citation Mills, Brandon, "Testosterone Use and Effects" (2013).
More information1001 West Broadway, Vancouver, BC V6H 4B1. Topical Finasteride
1001 West Broadway, Vancouver, BC V6H 4B1 Topical Finasteride 1 Topical finasteride is a solution containing the drug finasteride typically sold under the brand names Propecia and Proscar. The Finasteride
More informationTESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc.
GENCOR PACIFIC, INC. 920 E. Orangethorpe Avenue, Suite B, Anaheim, CA 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com gita@gencorpacific.com www.gencorpacific.com TESTOFEN
More informationRelationship between Aerobic Training and Testosterone Levels in Male Athletes
Relationship between Aerobic Training and Testosterone Levels in Male Athletes Siu Yuen Ng Biology 493 13 th December, 2010 Abstract Salivary testosterone levels of 11 athletes and 15 non athletes were
More informationFINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM
750 West Broadway Street Suite 905 Vancouver, BC M5Z 1K1 FAX: (604) 648-9003 vancouveroffice@donovanmedical.com FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM What is finasteride? Finasteride
More informationAndrogen deficiency in the aging male
Androgen deficiency in the aging male Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society for Male Reproduction and Urology The American Society for Reproductive
More informationThe Testosterone Quandary. Beth Crowder, PhD, APRN
The Testosterone Quandary Beth Crowder, PhD, APRN Objectives Define testosterone, the hypothalamic-pituitary-gonadotrophic axis, and normal blood levels List functions of testosterone and symptoms of low
More informationA mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men
European Journal of Endocrinology (2004) 151 241 249 ISSN 0804-4643 EXPERIMENTAL STUDY A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men Paul
More informationFemale testosterone level chart
Female testosterone level chart The Borg System is 100 % Female testosterone level chart Mar 23, 2015. Male, Female. Age: T Level (ng/dl):, Age: T Level (ng/dl):. 0-5 mo. 75-400, 0-5 mo. 20-80. 6 mos.-9
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: 5 mg SE/H/PSUR/0002/006 Date of FAR:
M0BCore Safety Profile Active substance: Finasteride Pharmaceutical form(s)/strength: 5 mg P-RMS: SE/H/PSUR/0002/006 Date of FAR: 16.05.2014 4.3 Contraindications Finasteride is not indicated for use in
More informationSELECT WHEY SOME THOUGHTS ON WHY WHEY PROTEIN CONTINUES TO BE CLINICALLY IMPORTANT
SELECT WHEY SOME THOUGHTS ON WHY WHEY PROTEIN CONTINUES TO BE CLINICALLY IMPORTANT Certainly, a legitimate concern about whey protein supplementation is allergenicity. However, while this concern is warranted,
More informationMI Androgen Deficiency Hypogonadism
MI Androgen Deficiency Hypogonadism WADA TUE Expert Group John A Lombardo, MD October 2014, Columbus, Ohio USA Hypothalamic-Pituitary-Gonadal Axis / 2 Hypogonadism/Androgen Deficiency Clinical syndrome:
More informationTREATMENT OPTIONS FOR MALE HYPOGONADISM
TREATMENT OPTIONS FOR MALE HYPOGONADISM Bruce Biundo, RPh, FACA PCCA Pharmacy Consulting Department Updated July 2012 Hypogonadism in men is primarily a state involving lower than expected levels of testosterone,
More informationAndrogenes and Antiandrogenes
Androgenes and Antiandrogenes Androgens The androgens are a group of steroids that have anabolic and/or masculinizing effects in both males and females. Testosterone [tess-toss-terone], the most important
More informationInappropriate Testosterone Billings
Inappropriate Testosterone Billings Carla Patrick-Fagan March 30, 2015 Truven Health Analytics Inc. All Rights Reserved. 1 Agenda Proposed in the 2015 analytic plan Steroid prescriptions Code of Federal
More informationOF THE one thousand generations of humans that have
0021-972X/98/$03.00/0 Vol. 83, No. 10 Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright 1998 by The Endocrine Society THERAPEUTIC PERSPECTIVE Issues in Testosterone Replacement
More informationAndrogens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent
Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent Androgens/Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred
More informationHGH for Sale Natural Anti-Aging Human Growth Hormone
HGH for Sale Natural Anti-Aging Human Growth Hormone Human growth hormone is one of the hottest supplement trends on the market, and now you can purchase top-quality HGH to be delivered right to your home!
More informationAFTER nearly six decades of intense controversy (1),
Journal of Gerontology: MEDICAL SCIENCES 2003, Vol. 58A, No. 12, 1103 1110 Copyright 2003 by The Gerontological Society of America Review Article The Mechanisms of Androgen Effects on Body Composition:
More informationAdverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function
Adverse effects of anabolic androgenic steroids abuse on gonadal function, glucose homeostasis and cardiovascular function Associate Professor Caroline Kistorp, Ph.D Department of Internal Medicine, Herlev
More informationLaboratoires Dom AVMM (Suisse) Inc. New Innovation in Peptide Therapy for Slimming
Laboratoires Dom AVMM (Suisse) Inc New Innovation in Peptide Therapy for Slimming Globally, Fat Facts 1 billion overweight adults 300 million obese adults A major risk for chronic diseases: Type 2 diabetes
More informationReproductive DHT Analyte Information
Reproductive DHT Analyte Information - 1 - DHT Introduction Dihydrotestosterone (DHT) together with other important steroid hormones such as testosterone, androstenedione (ASD) and dehydroepiandrosterone
More informationRobert Perlstein, M.D. Medical Officer. Center for Drug Evaluation and Research. U.S. Food & Drug Administration
-------------------- Robert Perlstein, M.D. Medical Officer Center for Drug Evaluation and Research U.S. Food & Drug Administration -------------------- Sentencing of Food and Drug Offenses Before the
More informationElements for a public summary
VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology Prostate gland enlargement is a common condition as men get older. Also called benign prostatic hyperplasia (BPH) and prostatic
More informationNutrition, supplements, and exercise
Nutrition, supplements, and exercise Walter R. Frontera, MD, PhD Professor and Chair Department of Physical Medicine and Rehabilitation Vanderbilt University School of Medicine And Medical Director of
More informationAffirming Care of the Transgender Patient
Mountain West AIDS Education and Training Center Affirming Care of the Transgender Patient Jessica Rongitsch, MD, FACP This presentation is intended for educational use only, and does not in any way constitute
More informationCreatine Versus Anabolic Steroids. Over the past few years, many athletes have been using performance-enhancing
Hester 1 Kyle Hester Instructor s Name ENGL 1013 Date Creatine Versus Anabolic Steroids Over the past few years, many athletes have been using performance-enhancing supplements on a regular basis. Two
More informationGonadal Steroids and Body Composition, Strength, and Sexual Function in Men
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men Joel S. Finkelstein, M.D., Hang Lee, Ph.D., Sherri-Ann
More informationIcd-10 low levels of testosterone
Icd-10 low levels of testosterone The Borg System is 100 % Icd-10 low levels of testosterone 1-10-2017 if your hormone levels are too high or too low, you may have a hormone disorder. Hormone diseases
More informationGrowth Hormone & Somatotropin are an Ergogenic Aid
Growth Hormone & Somatotropin are an Ergogenic Aid BPK 312 MARCH 28 2017 MICHAEL MORKOS PAUL SOURIAL DEL INGVALDSON Table of Contents 1. Hypothesis 2. Clinical Use 3. Mechanism of Action 4. Growth hormone
More informationGynaecomastia. Benign breast conditions information provided by Breast Cancer Care
Gynaecomastia This booklet tells you about gynaecomastia. It explains what gynaecomastia is, what causes it, how it s diagnosed and what will happen if it needs to be treated or followed up. Benign breast
More informationLEUCINE. - A major driving force for Muscle Protein Synthesis
LEUCINE - A major driving force for Muscle Protein Synthesis An article by Professor Don MacLaren, 2016. Leucine is one of the 9 essential amino acids that are required to be ingested by the body since
More informationMedical Policy Testosterone Therapy
Medical Policy Testosterone Therapy Subject: Testosterone Therapy Effective Date: April 2015 Overview: Testosterone cypionate, testosterone enanthate, testosterone undecanoate, and testosterone pellet
More informationPRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate)
PRODUCT INFORMATION TESTOVIRON DEPOT (testosterone enanthate) NAME OF THE MEDICINE Testosterone enanthate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of
More informationTestosterone Effects in Transmen
Transmen Testosterone Effects in Transmen EFFECT Skin oiliness/acne Facial/body hair growth Scalp hair loss Increased muscle mass/strength Fat redistribution Cessation of menses Clitoral enlargement Vaginal
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH) (an increase in size of the prostate that is not cancerous) is the most prevalent of all diseases
More informationSeptember 17, FDA background documents for the discussion of two major issues in testosterone replacement therapy (TRT):
JOINT MEETING FOR BONE, REPRODUCTIVE AND UROLOGIC DRUGS ADVISORY COMMITTEE (BRUDAC) AND THE DRUG SAFETY AND RISK MANAGEMENT ADVISORY COMMITTEE (DSARM AC) September 17, 2014 FDA background documents for
More informationPatent Foramen Ovale and Fitness
Guidelines for Patent Foramen Ovale and Fitness Proceedings Summary DAN/UHMS PFO and Fitness to Dive Workshop Introduction Prior to birth, oxygenated blood flows from the mother through the placenta to
More informationTestosterone as a Therapeutic Tool
330 Medicine Update 56 Testosterone as a Therapeutic Tool SV MADHU INTRODUCTION Testosterone preparations have been available for many years and have been used by physicians primarily to treat sexual problems.
More information2. Testosterone and Aging
2. Testosterone and Aging Shalender Bhasin, MD Thomas G. Travison, PhD Ravi Jasuja, PhD Carlo Serra, PhD Thomas W. Storer, PhD Shehzad Basaria, MD Case 2-1 A 78-year-old man requests evaluation for weakness,
More informationCONFÉRENCE À SUCCÈS EN SCIENCES DE LA VIE : ENDOCEUTICS
CONFÉRENCE À SUCCÈS EN SCIENCES DE LA VIE : ENDOCEUTICS 13 Septembre 2018 Quebec, Canada 1 ENDOCEUTICS No. 1 Innovative pharmaceutical company in menopausal women s health in the world 2 Facilities Head
More informationUpdates on Anti-doping and TUE Management in Paralympic Sport
International Paralympic Committee Updates on Anti-doping and TUE Management in Paralympic Sport Matthew Fedoruk, Ph.D. March 15, 2018 PyeongChang 2018 IPC Medical / Sports Science Committee Workshops
More informationSkin metabolism of steroid hormones as endogenous compounds?
Skin metabolism of steroid hormones as endogenous compounds? Van Luu-The Department of Molecular Medicine Laval University Québec, Canada This work has been supported by L Oréal Research Steroid hormones
More informationEvaluate the evidence for and against the use of testosterone to extend lifespan
1 Evaluate the evidence for and against the use of testosterone to extend lifespan Background and introduction Testosterone is a steroid hormone which was first isolated in 1935 (David, Dingemanse, Freud
More informationRisks and benefits of testosterone therapy in older men. Matthew Spitzer, Grace Huang, Shehzad Basaria, Thomas G. Travison and Shalender Bhasin
Risks and benefits of testosterone therapy in older men Matthew Spitzer, Grace Huang, Shehzad Basaria, Thomas G. Travison and Shalender Bhasin Abstract In young men (defined as age
More informationMonth/Year of Review: September 2013 Date of Last Review: December 2009
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2013 Oregon State University. All Rights
More informationSummary. Introduction. Dow Stough, MD
Original Contribution Blackwell Publishing ORIGINAL Inc CONTRIBUTION Dutasteride improves male pattern hair loss in a randomized study in identical twins Dow Stough, MD The Dermatology Clinic, Hot Springs,
More informationLeader: Anne Coble Voss, PhD, RD, LD, Abbott Nutrition, Columbus, OH
Discussion Leader: Anne Coble Voss, PhD, RD, LD, Abbott Nutrition, Columbus, OH Dr Tisdale: Dr Bosaeus, you suggested that the drive to synthesize acute-phase proteins by the liver was actually driving
More informationLIFETIME FITNESS HEALTHY NUTRITION. UNIT 2 Lesson 14 FLEXIBILITY LEAN BODY COMPOSITION
LIFETIME FITNESS HEALTHY NUTRITION MUSCULAR STRENGTH AEROBIC ENDURANCE UNIT 2 Lesson 14 FLEXIBILITY LEAN BODY COMPOSITION MUSCULAR ENDURANCE Created by Derek G. Becher B.P.E., B. Ed., AFLCA Resistance
More informationWhat is the difference with Whey, Casein, BCAA's, Glutamine, NO products?
Charles Glass - Mr. World / IFBB PRO Senior Executive Vice President Personal Trainers Association (PROPTA) PROPTA Master Trainer about Recov Bipeptides This is the best protein supplement I ever tried
More informationAre Steroids Worth the Risk?
Are Steroids Worth the Risk? Dominic has baseball on the brain. Just being good isn't enough he wants to be the best. He dreams of playing in the majors someday, but worries about the intense competition
More informationCurrent Data and Considerations Novel Testosterone Formulations
Current Data and Considerations Novel Testosterone Formulations 1 Current and Novel Therapeutic Options Module 4 2 Objectives Identify desirable characteristics of ideal testosterone formulations Review
More informationMedication Policy Manual
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Topic: Non-preferred, non-transdermal testosterone replacement therapy products (Android, Aveed, Androxy, Methitest,
More informationPHYSICIANS CIRCULAR FINASTERIDE PROSCAR. Tablet 5-Alpha Reductase Inhibitor
PHYSICIANS CIRCULAR FINASTERIDE PROSCAR Tablet 5-Alpha Reductase Inhibitor FINASTERIDE (PROSCAR) a synthetic 4-azasteroid compound, is a specific inhibitor of Type II 5α-reductase, an intracellular enzyme
More informationGrowth Hormone s Impact as a Safe Ergogenic Aid to Increase Body Size
Growth Hormone s Impact as a Safe Ergogenic Aid to Increase Body Size Point Argument: Growth Hormone is a Safe Ergogenic Aid to Increase Body Size Monica Chauhan Carissa Eastwood Emily Lefler Mar. 28,
More informationNatural estrogens estradiol estrone estriol
Estrogens Natural estrogens estradiol estrone estriol Nonsteroidal synthetic Diethylstilbestrol Chlorotrianisene Methallenestril Steroidal synthetic Ethinyl estradiol Mestranol Quinestrol To decrease some
More informationPerformance Enhancing Drugs in Sports
Performance Enhancing Drugs in Sports Mark D. Price, M.D., Ph.D Assistant Professor, Department of Orthopedic Surgery University of Massachusetts Medical School Historical Perspective 1889 Brown-Sequard
More informationGoing! Going! Gone! Your favorite slugger just hit a game winning homerun and you re
James Krein jvk2@uakron.edu Economic Essay on Something Curious The University of Akron September 8, 2006 Why Do Professional Athletes Take Steroids and Other Banned Substances? In this paper I will discuss
More informationNatural testosterone enhancement
Search Search pages & people Search Search Search pages & people Search Natural testosterone enhancement Buy Herbal T Natural Testosterone Booster: Increase Energy, Endurance, and Libido. Male Enhancement
More informationTestosterone Topical/Buccal/Nasal
BENEFIT APPLICATION Testosterone Topical/Buccal/Nasal DRUG POLICY Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations
More informationFoods, Spices and Herbs That Boost. Testosterone Naturally and Invigorate. Your Sex Drive. by David Blyweiss, M.D.
BOOSTERS Testosterone Boosters Foods, Spices and Herbs That Boost Testosterone Naturally and Invigorate Your Sex Drive by David Blyweiss, M.D. Copyright 2009 by UniScience Group Inc. All rights reserved.
More informationDr Tarza Jamal Pharmacology Lecture 2
Contraceptives and androgen hormone Contraceptives: Currently, interference with ovulation is the most common pharmacologic intervention for preventing pregnancy. Major classes of contraceptives 1. Combination
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Implantable Hormone Pellets Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5 References... 6 Effective Date...
More informationBuy The Complete Version of This Book at Booklocker.com:
Maintain youthful libido, sexual function, cardiovascular, bone, muscle, overall health. The Gentleman's Guide to the Fountain of Youth Buy The Complete Version of This Book at Booklocker.com: http://www.booklocker.com/p/books/2056.html?s=pdf
More informationDrugs & Exercise. Lesson. By Carone Fitness
Lesson Drugs & Exercise By Carone Fitness Being physically fit and using drugs just don t mix. Unfortunately, there are some athletes that do use drugs for recreation or to enhance performance. There are
More informationUCLA Nutrition Noteworthy
UCLA Nutrition Noteworthy Title Protein and Amino Acid Supplementation for Resistance Training: Are We Being Sold Products That We Don t Need? Permalink https://escholarship.org/uc/item/5q0844bz Journal
More informationThe use of testosterone is increasing in middle-aged and
JCEM ONLINE Brief Report Endocrine Care A Randomized Pilot Study of ly Cycled Testosterone Replacement or Testosterone Replacement Versus Placebo in Older Men Melinda Sheffield-Moore,* E. Lichar Dillon,*
More informationMonitoring Hormone Therapy Mark Newman, M.S. President of Precision Analytical Inc.
Mr Mark Newman Monitoring Hormone Therapy Mark Newman, M.S. President of Precision Analytical Inc. 2 Avoiding Pitfalls in (B)HRT Monitoring and Picking the Right Lab Test Objectives: Outline how expected
More informationAnabolic Androgenic Steroids
Anabolic Androgenic Steroids 1 / 6 2 / 6 3 / 6 Anabolic Androgenic Steroids What are anabolic steroids? Anabolic steroids are synthetic, or human-made, variations of the male sex hormone testosterone.
More informationCHAPTER XVI PDL 101 HUMAN ANATOMY & PHYSIOLOGY. Ms. K. GOWRI. M.Pharm., Lecturer.
CHAPTER XVI PDL 101 HUMAN ANATOMY & PHYSIOLOGY Ms. K. GOWRI. M.Pharm., Lecturer. Muscle Cell Metabolism Muscle Cells Provide ATP to Drive the Crossbridge Cycle The sources of ATP: Available ATP in the
More informationClinical Policy: Testosterone Reference Number: AZ.CP.PHAR.02 Effective Date: Last Review Date: Line of Business: Arizona Medicaid
Clinical Policy: Reference Number: AZ.CP.PHAR.02 Effective Date: 11.16.16 Last Review Date: 09.12.18 Line of Business: Arizona Medicaid Revision Log See Important Reminder at the end of this policy for
More informationPhysical activity has a number of benefits
Health Policy Brief September 2018 Walking Among California Adults Susan H. Babey, Joelle Wolstein, and Allison L. Diamant SUMMARY: This policy brief describes two types of walking among California adults:
More informationClinical impact of type I and type II 5 alpha-reductase inhibition in prostatic disease: review and update 아주대학교김선일
Clinical impact of type I and type II 5 alpha-reductase inhibition in prostatic disease: review and update 아주대학교김선일 Development of 5ARI Discovery of 5AR type I and type II Pharmacodynamic and pharmacokinetic
More informationAssociate Professor Geoff Braatvedt
Associate Professor Geoff Braatvedt Endocrinologist Diabetologist and Physician Green Lane and Auckland City Hospitals Auckland 14:00-14:55 WS #145: Approach to Low Testosterone Values 15:05-16:00 WS #157:
More informationFINCAR Tablets (Finasteride)
Published on: 10 Jul 2014 FINCAR Tablets (Finasteride) Composition FINCAR Tablets Each film-coated tablet contains: Finasteride USP - 5 mg Dosage Form Tablet Pharmacology Pharmacodynamics Mechanism of
More informationTESTOFEN. Anabolic & Androgenic Activity GENCOR PACIFIC, INC. Fenugreek Extract standardized for FENUSIDE TM. Copyright 2005 by Gencor Pacific, Inc.
GENCOR PACIFIC, INC. 920E. Orangethorpe Avenue, Suite B, Anaheim, CA. 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com manu@gencorpacific.com www.gencorpacific.com TESTOFEN
More informationFormally known as anabolic steroids or anabolic-androgenic steroids, but they are sometimes called 'roids', 'gear' or 'juice'.
Steroids What are steroids? Steroids are drugs that help the growth and repair of muscle tissue. They are synthetic hormones that imitate male sex hormones, specifically testosterone. Steroids can increase
More informationAn overview of the endocrinology of skeletal muscle
Review TRENDS in Endocrinology and Metabolism Vol.15 No.3 April 2004 An overview of the endocrinology of skeletal muscle Melinda Sheffield-Moore 2 and Randall J. Urban 1 1 University of Texas Medical Branch,
More informationUnderstanding combined oral contraception
Understanding combined oral contraception Paula Briggs, FFSRH Consultant in Community Sexual and Reproductive Health Southport and Ormskirk NHS Hospital Trust May Logan Centre, Bootle, L20 5DQ paulaeb@aol.com
More informationRisks Versus Benefits of Testosterone Therapy in Elderly Men
REVIEW ARTICLE Drugs & Aging 1999 Aug; 15 (2): 131-142 1170-229X/99/0008-0131/$06.00/0 Adis International Limited. All rights reserved. Risks Versus Benefits of Testosterone Therapy in Elderly Men Shehzad
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationMODULE #8 - Lesson 3
MODULE #8 - Lesson 3 21st Century Man: Testosterone and Andropause Module 8 - Lesson 3 21st Century Man: Testosterone and Andropause Testosterone and andropause are 2 pressing issues for men in the 21st
More informationBiology Paper, CSE Style (Martin)
Biology Paper, CSE Style (Martin) Hypothermia, the Diving Reflex, and Survival Full title, writer s name, name of course, instructor s name, and date (all centered). Briana Martin Biology 281 Professor
More informationAnavar For Sale Oxandrolone
Anavar For Sale Oxandrolone Anavar (oxandrolone C 19 H 30 O 3 ) is an anabolic steroid that provides outstanding results. The Anavar steroid is a synthesized version of testosterone that boosts lean muscle
More information